| 208.37 -0.62 (-0.3%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 255 | 1-year : | 267.02 |
| Resists | First : | 218.32 | Second : | 228.61 |
| Pivot price | 210.1 |
|||
| Supports | First : | 201.66 | Second : | 167.78 |
| MAs | MA(5) : | 208.49  |
MA(20) : | 209.25 |
| MA(100) : | 221.12 |
MA(250) : | 208.83 |
|
| MACD | MACD : | -2.8 |
Signal : | -3.3 |
| %K %D | K(14,3) : | 36.7 |
D(3) : | 37.6 |
| RSI | RSI(14): 43.5 |
|||
| 52-week | High : | 241.11 | Low : | 164.57 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ABBV ] has closed above bottom band by 36.2%. Bollinger Bands are 28.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 212.84 - 213.89 | 213.89 - 214.74 |
| Low: | 204.91 - 206.34 | 206.34 - 207.5 |
| Close: | 206.38 - 208.53 | 208.53 - 210.27 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Sat, 18 Apr 2026
Asset Management One Co. Ltd. Has $209.74 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Fri, 17 Apr 2026
AbbVie Inc. (NYSE:ABBV) Short Interest Update - MarketBeat
Fri, 17 Apr 2026
AbbVie Inc. (ABBV): A Bull Case Theory - MSN
Fri, 17 Apr 2026
Merit Financial Group LLC Has $21.32 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Thu, 16 Apr 2026
Cwm LLC Boosts Holdings in AbbVie Inc. $ABBV - MarketBeat
Thu, 16 Apr 2026
Diversified Management Inc. Takes Position in AbbVie Inc. $ABBV - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 1,770 (M) |
| Held by Insiders | 1.77e+009 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 22,880 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.925e+010 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 6.9 % |
| Operating Margin | 34.1 % |
| Return on Assets (ttm) | 9.8 % |
| Return on Equity (ttm) | 6 % |
| Qtrly Rev. Growth | 6.116e+010 % |
| Gross Profit (p.s.) | 30.3 |
| Sales Per Share | 681.81 |
| EBITDA (p.s.) | 1.32727e+011 |
| Qtrly Earnings Growth | 2.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 19,030 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.3 |
| Price to Cash Flow | -37.17 |
| Dividend | 0 |
| Forward Dividend | 2.511e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|